News articles about Surface Oncology (NASDAQ:SURF) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Surface Oncology earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.8596708524885 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Minomic Secures Key Patent in the United States and China (businesswire.com)
- New Therapy for Rare Lymphoma (technology.org)
- Alopecia Areata Trial Results, Skin Oncology Top EADV Agenda (medscape.com)
- Surface Oncology to Present at the Baird 2018 Global Healthcare Conference (finance.yahoo.com)
Several research analysts have commented on SURF shares. Cowen reiterated a “buy” rating on shares of Surface Oncology in a report on Tuesday, August 14th. Zacks Investment Research upgraded shares of Surface Oncology from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a report on Tuesday, July 24th. Evercore ISI started coverage on shares of Surface Oncology in a report on Monday, May 14th. They set an “outperform” rating and a $26.00 price target for the company. Finally, Goldman Sachs Group started coverage on shares of Surface Oncology in a report on Monday, May 14th. They set a “neutral” rating and a $17.00 price target for the company.
NASDAQ SURF traded up $0.36 on Wednesday, hitting $10.57. 79,205 shares of the stock were exchanged, compared to its average volume of 231,458. Surface Oncology has a fifty-two week low of $8.64 and a fifty-two week high of $18.18.
Surface Oncology (NASDAQ:SURF) last posted its quarterly earnings results on Tuesday, August 14th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.03. The firm had revenue of $2.43 million for the quarter. research analysts expect that Surface Oncology will post -2.1 EPS for the current fiscal year.
About Surface Oncology
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27.
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.